ADMA Biologics (NASDAQ:ADMA)‘s stock had its “buy” rating reaffirmed by equities research analysts at Maxim Group in a research note issued on Monday, MarketBeat reports. They presently have a $8.00 target price on the biotechnology company’s stock, down from their previous target price of $13.00. Maxim Group’s target price points to a potential upside of 206.51% from the stock’s current price.

The analysts wrote, “Recent financing: ADMA completed an equity financing in November, raising $42M and also completed a $30M debt refinancing of which $6M in cash remains. Combined with $13.6M reported in 3Q17, we estimate ADMA has $60M in cash on the balance sheet.””

Several other equities research analysts also recently weighed in on the company. Raymond James Financial raised ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a report on Tuesday, November 14th. ValuEngine downgraded ADMA Biologics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

ADMA Biologics (NASDAQ ADMA) traded down $0.15 during mid-day trading on Monday, hitting $2.61. The stock had a trading volume of 419,900 shares, compared to its average volume of 63,785. ADMA Biologics has a 1-year low of $2.01 and a 1-year high of $5.79. The company has a debt-to-equity ratio of 2.26, a current ratio of 2.36 and a quick ratio of 1.35.

In other ADMA Biologics news, Director Eric I. Richman bought 25,000 shares of ADMA Biologics stock in a transaction on Thursday, November 9th. The stock was bought at an average price of $2.15 per share, with a total value of $53,750.00. Following the completion of the acquisition, the director now owns 31,300 shares in the company, valued at $67,295. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Adam S. Grossman bought 485,000 shares of ADMA Biologics stock in a transaction on Thursday, November 9th. The stock was acquired at an average cost of $2.15 per share, with a total value of $1,042,750.00. The disclosure for this purchase can be found here. In the last three months, insiders acquired 526,500 shares of company stock valued at $1,131,975. 60.44% of the stock is owned by corporate insiders.

A hedge fund recently raised its stake in ADMA Biologics stock. Iguana Healthcare Management LLC raised its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 565,000 shares of the biotechnology company’s stock after acquiring an additional 415,000 shares during the quarter. Iguana Healthcare Management LLC owned 2.19% of ADMA Biologics worth $1,740,000 as of its most recent filing with the SEC. 32.78% of the stock is owned by institutional investors.

WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/11/adma-biologics-adma-given-a-8-00-price-target-by-maxim-group-analysts.html.

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.